Spero Therapeutics (SPRO) Profit After Tax (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.89% |
| Dec 31, 2025 | 526.33% |
| Sep 30, 2025 | -334.24% |
| Jun 30, 2025 | 87.74% |
| Mar 31, 2025 | 33.66% |
| Dec 31, 2024 | -22.22% |
| Sep 30, 2024 | 4.27% |
| Jun 30, 2024 | -40.99% |
| Mar 31, 2024 | -124.74% |
| Dec 31, 2023 | 1,700.19% |
| Sep 30, 2023 | 73.14% |
| Jun 30, 2023 | 10.19% |
| Mar 31, 2023 | -149.55% |
| Dec 31, 2022 | 329.30% |
| Sep 30, 2022 | 59.30% |
| Jun 30, 2022 | 12.63% |
| Mar 31, 2022 | -12.11% |
| Dec 31, 2021 | -30.03% |
| Sep 30, 2021 | -21.26% |
| Jun 30, 2021 | 4.38% |
| Mar 31, 2021 | -4.51% |
| Dec 31, 2020 | 1.85% |
| Sep 30, 2020 | -8.20% |
| Jun 30, 2020 | 24.75% |
| Mar 31, 2020 | 6.92% |
| Dec 31, 2019 | -41.03% |
| Sep 30, 2019 | -34.73% |
| Jun 30, 2019 | -159.27% |
| Mar 31, 2019 | 52.15% |
| Dec 31, 2018 | -1.30% |
| Sep 30, 2018 | -5.09% |
| Jun 30, 2018 | 6.46% |
| Mar 31, 2018 | 23.25% |
| Dec 31, 2017 | -40.88% |
| Sep 30, 2017 | -0.83% |
| Jun 30, 2017 | -66.15% |
| Mar 31, 2017 | 28.32% |
| Dec 31, 2016 | -29.78% |